Literature DB >> 27989430

Osimertinib effective in EGFR T790M-positive lung cancer.

Susan Mayor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27989430     DOI： 10.1016/S1470-2045(16)30654-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  9 in total

Review 1.  Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.

Authors:  Roberto Chalela; Víctor Curull; César Enríquez; Lara Pijuan; Beatriz Bellosillo; Joaquim Gea
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

2.  TROY Modulates Cancer Stem-Like Cell Properties and Gefitinib Resistance Through EMT Signaling in Non-Small Cell Lung Cancer.

Authors:  Linying Wu; Yuman Yu; Liming Xu; Xiaoling Wang; Jianying Zhou; Yuehong Wang
Journal:  Front Genet       Date:  2022-05-13       Impact factor: 4.772

3.  Detection and monitoring of driver mutations by next-generation sequencing in squamous cell lung cancer patient and possible predictive biomarker of third generation EGFR-tyrosine kinase inhibitors.

Authors:  Xiaoyan Shen; Jie Shen; Hang Zhang; Yuxin Cheng; Yang Yang; Jiahui Gao; Yu Zhang; Rutian Li; Baorui Liu; Lifeng Wang
Journal:  Thorac Cancer       Date:  2017-11-16       Impact factor: 3.500

4.  Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series.

Authors:  Paul Zarogoulidis; Aggeliki Rapti; Chrysanthi Sardeli; Panagiotis Chinelis; Anastasia Athanasiadou; Katerina Paraskevaidou; Anastasios Kallianos; Lemonia Veletza; Georgia Trakada; Wolfgang Hohenforst-Schmidt; Haidong Huang
Journal:  Respir Med Case Rep       Date:  2017-05-30

5.  PUMA mediates the anti-cancer effect of osimertinib in colon cancer cells.

Authors:  Lingchuan Guo; Shan Huang; Xinwei Wang
Journal:  Onco Targets Ther       Date:  2017-11-03       Impact factor: 4.147

Review 6.  Nanomedicines for Overcoming Cancer Drug Resistance.

Authors:  Tingting Hu; Hanlin Gong; Jiayue Xu; Yuan Huang; Fengbo Wu; Zhiyao He
Journal:  Pharmaceutics       Date:  2022-08-01       Impact factor: 6.525

7.  Compound Capecitabine Colon-Targeted Microparticle Prepared by Coaxial Electrospray for Treatment of Colon Tumors.

Authors:  Ruiqi Chen; Ruidong Zhai; Chao Wang; Shulong Liang; Jing Wang; Zhepeng Liu; Wenlin Li
Journal:  Molecules       Date:  2022-09-03       Impact factor: 4.927

8.  Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib.

Authors:  Yaping Long; Qi Xiong; Qi Song; Yao Li; Xiaoyan Li; Boyu Qin; Ziwei Huang; Yi Hu; Bo Yang
Journal:  Thorac Cancer       Date:  2021-12-27       Impact factor: 3.500

9.  MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.

Authors:  Reheman Yiming; Yasuto Takeuchi; Tatsunori Nishimura; Mengjiao Li; Yuming Wang; Makiko Meguro-Horike; Takashi Kohno; Shin-Ichi Horike; Asuka Nakata; Noriko Gotoh
Journal:  Cancer Sci       Date:  2021-07-13       Impact factor: 6.716
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.